Canada· CA-DIN-01989987
MAGNEVIST
A gadopentetsäure product containing gadopentetate dimeglumine, registered in Canada by BAYER INC. The same ATC class is registered in 3 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Gadopentetsäure is registered in 3 of 19 countries.
Countries holding a registration under ATC V08CA01 (gadopentetsäure), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 2 of them publish a price we can compare per daily dose
Gadopentetsäure · ATC V08CA01
3 / 19 countries
- Belgiumprice
- Canada
- Finlandprice
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- GADOPENTETATE DIMEGLUMINE
- Manufacturer
- BAYER INC
- Country
- Canada (CA)
- ATC code
- V08CA01
- ATC class
- Gadopentetsäure
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Gadopentetsäure in 3 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumMagnevist 0,5 mmol/mlBayer
- GermanyMagnevistEurocontrast Gmbh
- SwedenMagnevist 2 mmol/l Injektionsvätska, lösning i förfylld sprutaBayer AB
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Germany · Magnevist
- United Kingdom (Northern Ireland) · Magnevist
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/64320451-8d48-4e0e-80ec-61d1632d7257 GET /v1/drugs/64320451-8d48-4e0e-80ec-61d1632d7257?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "01989987",
"form": "SOLUTION",
"class": "Human",
"routes": [
"INTRAVENOUS"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "V08CA01",
"schedule": [
"Ethical"
],
"drug_code": "13384",
"strengths": [
"469 MG"
],
"ahfs_class": null,
"substances": [
"GADOPENTETATE DIMEGLUMINE"
],
"product_categorization": null
}See everything about gadopentetsäure.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.